Table 1.
Demographic and clinical data of HCC and non-malignant chronic liver disease patients.
Table 2.
Clinicopathological characteristics of HCC patients.
Fig 1.
Differential expression of serum miRNA levels in HCC and healthy controls.
Relative expression of miRNAs miR-19a (P = 0.0002), miR-296 (P<0.0001), miR-130a (P<0.0001), miR-195 (P = 0.04), miR-192 (P<0.0001), miR-34a (P<0.0001), and miR-146a (P<0.0001) in serum of HCC (n = 112) compared to healthy controls (n = 42). Data are presented as median with interquartile range. Data were analyzed by Mann-Whitney U-test.* means statistical significance (P<0.05).
Fig 2.
Differential expression of serum miRNA levels in HCC and CLD patients.
The box represents the 25%-75% percentiles; the line inside the box represents the median and the upper and lower lines representing the 10%-90% percentiles of fold change in expression levels of studied miRNAs in serum of CLD (n = 125) and HCC patients (n = 112). Data were analyzed by Mann-Whitney U-test.
Fig 3.
Signature of serum miRNAs relative expression during HCV-related liver disease progression.
Panel (A) represents fold change of miRNA expression levels in early fibrosis (F1-F2, n = 75), late fibrosis (F3-F4, n = 50), and HCC (n = 112) groups. Comparison between F1-F2 vs F3-F4 or F3-F4 vs HCC was analyzed by Mann-Whitney U-test. Panel (B) represents detailed analysis of miRNA relative expression levels at different fibrosis stages (F1, n = 45, F2, n = 30, F3, n = 18, F4, n = 32) and HCC (n = 112). Comparison was done by Kruskal-Wallis test. Mann-Whitney U-test was used to compare F1-F3 vs F4 or F4 vs HCC. The box represents the 25%-75% percentiles; the line inside the box represents the median and the upper and lower lines representing the 10%-90% percentiles.
Fig 4.
Serum miRNAs as diagnostic biomarkers to differentiate HCC patients from healthy controls.
ROC curve analysis of serum miRNAs as diagnostic biomarkers differentiating HCC patients (n = 112) from healthy controls (n = 42).
Fig 5.
Serum miRNAs as diagnostic biomarkers to differentiate HCC from non-malignant CLD.
ROC curve analysis of serum miRNAs as diagnostic biomarkers differentiating HCC patients (n = 112) from CLD (n = 125).
Fig 6.
Serum miRNAs as diagnostic biomarkers to differentiate HCC patients from late fibrosis (F3-F4) subgroup.
ROC curve analysis of serum miRNAs as diagnostic biomarkers differentiating HCC (n = 112) from F3-F4 patients (n = 50).
Table 3.
Diagnostic performances of serum miRNAs to discriminate HCC patients from healthy controls, non-malignant CLD patients, and late fibrosis (F3-F4) subgroup.
Table 4.
Logistic regression analysis of miRNAs.
Fig 7.
Diagnostic performance of the miRNA panel.
AUCs of the miRNA panel (A) and miRNA panel in differentiating HCC from healthy controls (B), CLD (C), and F3-F4 patients (D).
Fig 8.
Comparison of AUC of the miRNA panel with that of AFP.
AUCs of the miRNA panel and AFP in differentiating HCC from healthy controls (A), CLD (B), and F3-F4 patients (C).
Fig 9.
Correlations between serum miRNAs levels in HCC group.
A correlation map with a blue-red (cold-hot) scale. The blue color corresponds to a correlation close to -1 and the red color corresponds to a correlation close to 1. Green corresponds to a correlation close to 0. Correlations are made by spearman correlation.